- Home
- AZPN vs INCY Comparison
AZPN vs INCY Comparison
Compare AZPN & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZPN
- INCY
- Stock Information
- Founded
- AZPN 1981
- INCY 1991
- Country
- AZPN United States
- INCY United States
- Employees
- AZPN N/A
- INCY N/A
- Industry
- AZPN EDP Services
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- AZPN Technology
- INCY Health Care
- Exchange
- AZPN Nasdaq
- INCY Nasdaq
- Market Cap
- AZPN 13.3B
- INCY 12.2B
- IPO Year
- AZPN 1994
- INCY 1993
- Fundamental
- Price
- AZPN $225.10
- INCY $61.26
- Analyst Decision
- AZPN Strong Buy
- INCY Buy
- Analyst Count
- AZPN 4
- INCY 18
- Target Price
- AZPN $224.50
- INCY $71.13
- AVG Volume (30 Days)
- AZPN 219.4K
- INCY 1.8M
- Earning Date
- AZPN 08-06-2024
- INCY 10-29-2024
- Dividend Yield
- AZPN 0.23%
- INCY N/A
- EPS Growth
- AZPN N/A
- INCY N/A
- EPS
- AZPN N/A
- INCY 0.44
- Revenue
- AZPN $1,127,482,000.00
- INCY $3,857,014,000.00
- Revenue This Year
- AZPN $7.23
- INCY $14.43
- Revenue Next Year
- AZPN $8.02
- INCY $9.88
- P/E Ratio
- AZPN N/A
- INCY $140.24
- Revenue Growth
- AZPN 7.98
- INCY 9.78
- 52 Week Low
- AZPN $162.26
- INCY $50.27
- 52 Week High
- AZPN $235.10
- INCY $70.36
- Technical
- Relative Strength Index (RSI)
- AZPN 60.68
- INCY 39.20
- Support Level
- AZPN $221.74
- INCY $61.15
- Resistance Level
- AZPN $231.90
- INCY $67.09
- Average True Range (ATR)
- AZPN 5.94
- INCY 1.73
- MACD
- AZPN 0.50
- INCY -0.23
- Stochastic Oscillator
- AZPN 58.28
- INCY 1.74
About AZPN Aspen Technology Inc.
Aspen Technology is a global leader in asset optimization software, enabling customers within capital-intensive industries to design, operate and maintain their functions to meet their profitability, safety, and sustainability goals. The heritage business of AspenTech was founded in 1981 and provides software solutions purposed to optimize engineering, manufacturing, and supply chain and asset management functions. In 2021, Emerson Electric traded over $6 billion in cash and its Open Systems International (digital grid management) and subsurface science and engineering businesses for 55% of AspenTech's shares. The new AspenTech is the combination of heritage Aspen, OSI, and SSE and serves more than 3,000 customers across 40 countries.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.